"10.1371_journal.pone.0028380","plos one","2011-12-15T00:00:00Z","Renaud Greget; Fabien Pernot; Jean-Marie C Bouteiller; Viviane Ghaderi; Sushmita Allam; Anne Florence Keller; Nicolas Ambert; Arnaud Legendre; Merdan Sarmis; Olivier Haeberle; Michel Faupel; Serge Bischoff; Theodore W Berger; Michel Baudry","Rhenovia Pharma, Mulhouse, France; MIPS, Universit√© de Haute Alsace, Mulhouse, France; Neuroscience Program, University of Southern California, Los Angeles, California, United States of America; Department of Biomedical Engineering, University of Southern California, Los Angeles, California, United States of America","Conceived and designed the experiments: MB TWB SB OH MF. Performed the experiments: RG J-MCB VG NA SA. Analyzed the data: MB FP AFK RG. Contributed reagents/materials/analysis tools: AL MS. Wrote the paper: RG FP MB.","MB, TB and JMB have a conflict of interest. The University of Southern California holds an equity interest in Rhenovia Pharma, and has also received licensing income from Rhenovia Pharma. Rhenovia Pharma received funding from a commercial source (Alsace Business Angel). This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials. All authors except OH are employees or consultants of Rhenovia Pharma. This does not affect the authors adherence to all the PLoS ONE policies on sharing data and materials. There are no other other relevant declarations relating to employment, consultancy, patents, products in development or marketed products, etc.","2011","12","Renaud Greget","RG",14,TRUE,5,5,4,3,TRUE,TRUE,FALSE,0,NA,FALSE
